Qiagen (QGEN) investor relations material

Business performance and demand trends

• Q1 showed mixed results, with most growth drivers performing well but QuantiFERON impacted by U.S. immigration testing changes and Middle East instability, leading to a $35 million revenue reduction.

• QuantiFERON is expected to see flattish to slightly negative growth in Q2, slight positive in Q3, and normalized growth in Q4.

• Four out of five growth pillars delivered or exceeded expectations in Q1 2026.

• OEM deals were removed from guidance to ensure forecasts are realistic, reflecting a cautious approach after the guidance reset.

• Life science guidance was cut due to weaker academic/government outlook and OEM headwinds, totaling a $35–40 million impact.

Product and portfolio developments

• Sample technologies and QIAcuity dPCR showed strong double-digit growth, with Parse Biosciences integration progressing well.

• QIAstat-Dx expanded its menu and entered new markets, including bloodstream infection testing in Europe.

• Parse technology is gaining traction in pharma and translational research, with expectations to exceed $40 million in 2026.

• New product launches like QIAsprint and QIAsymphony are expected to drive $20 million incremental revenue in H2.

• QuantiFERON faced a decline due to lower immigration testing but remains a global leader in latent TB detection.

Competitive landscape and technology leadership

• Competitive dynamics in TB testing favor the company due to critical marker inclusion and automation partnerships, especially with Inpeco.

• Inpeco partnership will automate front-end workflow, providing a unique, fully automated TB testing solution.

• Leading positions in sample preparation, digital PCR, syndromic testing, and bioinformatics for genomics.

• Expansion into high-growth markets such as single-cell analysis through Parse Biosciences.

• AI-driven solutions and SaaS models are central to future growth and differentiation.